Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction

Dominika Kanikowska, Malgorzata Pyda, Katarzyna Korybalska, Stefan Grajek, Maciej Lesiak, Andrzej Brȩborowicz, Janusz Witowski

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI). It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI. We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI) who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a single university centre with primary percutaneous coronary intervention (PCI). The non-survivors (6.3%) displayed most of typical risk factors for poor outcome. In addition they had significantly higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to increase with age and we could confirm a significant correlation between patients' calendar age and circulating IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients' age but they did not independently relate to patients' outcome. Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI. It is important to recognize that, because of the small group of patients who died (N = 10), the results must be interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further validated in a larger set of patients.

Original languageEnglish (US)
Article number23
JournalImmunity and Ageing
Volume11
Issue number1
DOIs
StatePublished - Dec 4 2014
Externally publishedYes

Fingerprint

Interleukin-6
Mortality
Myocardial Infarction
ST Elevation Myocardial Infarction
Percutaneous Coronary Intervention
Survivors
Regression Analysis
Cytokines
Serum

Keywords

  • Aging
  • Interleukin-6
  • Mortality
  • Myocardial infarction

ASJC Scopus subject areas

  • Immunology
  • Aging

Cite this

Kanikowska, D., Pyda, M., Korybalska, K., Grajek, S., Lesiak, M., Brȩborowicz, A., & Witowski, J. (2014). Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction. Immunity and Ageing, 11(1), [23]. https://doi.org/10.1186/s12979-014-0023-7

Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction. / Kanikowska, Dominika; Pyda, Malgorzata; Korybalska, Katarzyna; Grajek, Stefan; Lesiak, Maciej; Brȩborowicz, Andrzej; Witowski, Janusz.

In: Immunity and Ageing, Vol. 11, No. 1, 23, 04.12.2014.

Research output: Contribution to journalArticle

Kanikowska, D, Pyda, M, Korybalska, K, Grajek, S, Lesiak, M, Brȩborowicz, A & Witowski, J 2014, 'Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction', Immunity and Ageing, vol. 11, no. 1, 23. https://doi.org/10.1186/s12979-014-0023-7
Kanikowska, Dominika ; Pyda, Malgorzata ; Korybalska, Katarzyna ; Grajek, Stefan ; Lesiak, Maciej ; Brȩborowicz, Andrzej ; Witowski, Janusz. / Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction. In: Immunity and Ageing. 2014 ; Vol. 11, No. 1.
@article{dc37a9afa67543dfb008a7f951a9737a,
title = "Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction",
abstract = "Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI). It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI. We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI) who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a single university centre with primary percutaneous coronary intervention (PCI). The non-survivors (6.3{\%}) displayed most of typical risk factors for poor outcome. In addition they had significantly higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to increase with age and we could confirm a significant correlation between patients' calendar age and circulating IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients' age but they did not independently relate to patients' outcome. Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI. It is important to recognize that, because of the small group of patients who died (N = 10), the results must be interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further validated in a larger set of patients.",
keywords = "Aging, Interleukin-6, Mortality, Myocardial infarction",
author = "Dominika Kanikowska and Malgorzata Pyda and Katarzyna Korybalska and Stefan Grajek and Maciej Lesiak and Andrzej Brȩborowicz and Janusz Witowski",
year = "2014",
month = "12",
day = "4",
doi = "10.1186/s12979-014-0023-7",
language = "English (US)",
volume = "11",
journal = "Immunity and Ageing",
issn = "1742-4933",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction

AU - Kanikowska, Dominika

AU - Pyda, Malgorzata

AU - Korybalska, Katarzyna

AU - Grajek, Stefan

AU - Lesiak, Maciej

AU - Brȩborowicz, Andrzej

AU - Witowski, Janusz

PY - 2014/12/4

Y1 - 2014/12/4

N2 - Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI). It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI. We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI) who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a single university centre with primary percutaneous coronary intervention (PCI). The non-survivors (6.3%) displayed most of typical risk factors for poor outcome. In addition they had significantly higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to increase with age and we could confirm a significant correlation between patients' calendar age and circulating IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients' age but they did not independently relate to patients' outcome. Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI. It is important to recognize that, because of the small group of patients who died (N = 10), the results must be interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further validated in a larger set of patients.

AB - Interleukin-6 (IL-6) is an inflammatory cytokine whose levels increase significantly during myocardial infarction (MI). It has been hypothesised that the concentrations of IL-6 at admission may be useful in prognosticating long-term outcomes. It is unclear, however, whether IL-6 could improve the prognosis of early mortality in MI. We have compared serum IL-6 levels and analysed the disease course in 158 patients with ST-elevation MI (STEMI) who either survived (n = 148) or died (n = 10) within 30 days following the admission. Patients were treated in a single university centre with primary percutaneous coronary intervention (PCI). The non-survivors (6.3%) displayed most of typical risk factors for poor outcome. In addition they had significantly higher concentrations of IL-6 at hospital admission (median values 8.5 vs. 2.0 pg/ml; p = 0.038). However, they were also significantly older than the survivors (median values 72 vs. 57 years; p = 0.0001). IL-6 levels are known to increase with age and we could confirm a significant correlation between patients' calendar age and circulating IL-6 (p = 0.009). Regression analysis revealed that IL-6 concentrations were significantly affected by patients' age but they did not independently relate to patients' outcome. Such results indicate that circulating IL-6 at admission may be of limited value in predicting early mortality in STEMI. It is important to recognize that, because of the small group of patients who died (N = 10), the results must be interpreted with caution. Therefore, we stress that these results should be viewed as preliminary and further validated in a larger set of patients.

KW - Aging

KW - Interleukin-6

KW - Mortality

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84924917824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924917824&partnerID=8YFLogxK

U2 - 10.1186/s12979-014-0023-7

DO - 10.1186/s12979-014-0023-7

M3 - Article

VL - 11

JO - Immunity and Ageing

JF - Immunity and Ageing

SN - 1742-4933

IS - 1

M1 - 23

ER -